Jacobs Levy Equity Management’s Maravai LifeSciences MRVI Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Buy	458,901 +297,809	+185%	+$1.01M	0.01%	663
2025 Q4	$524K	Sell	161,092 -37,807	-19%	-$127K	﹤0.01%	791
2025 Q3	$571K	Sell	198,899 -8,840	-4%	-$22.6K	﹤0.01%	799
2025 Q2	$501K	Sell	207,739 -285,843	-58%	-$601K	﹤0.01%	883
2025 Q1	$1.09M	Buy	493,582 +401,673	+437%	+$1.59M	﹤0.01%	793
2024 Q4	$501K	Buy	+91,909	New	+$591K	﹤0.01%	816
2024 Q2	–	Sell	-57,076	Closed	-$495K	–	1014
2024 Q1	$495K	Sell	57,076 -114,736	-67%	-$776K	﹤0.01%	817
2023 Q4	$1.13M	Buy	+171,812	New	+$1.11M	0.01%	697

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management's MRVI Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Maravai LifeSciences (MRVI) stake by 185% in Q1 2026, buying an estimated $1.01M and bringing the position to 458,901 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #663.

Jacobs Levy Equity Management first reported a position in MRVI in Q4 2023 and has held it in 8 quarters since. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Jacobs Levy Equity Management held 458,901 shares of Maravai LifeSciences worth $1.3M as of Q1 2026.
Jacobs Levy Equity Management bought 297,809 Maravai LifeSciences shares in Q1 2026, an estimated $1.01M.
Maravai LifeSciences made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #663 holding.
Jacobs Levy Equity Management first reported a position in Maravai LifeSciences in Q4 2023 and has held it in 8 quarters since.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.